ATI Stock Recent News
ATI LATEST HEADLINES
Aug. 1 tariff deadlines and a potential firing of Fed Chair Powell, according to reports, are reintroducing uncertainty for the markets, which have been volatile in both directions, despite major US indices notching new peaks. But who will bear the brunt of tariff increases? New tariff threats on the EU, Canada, and Mexico could impact consumer spending, which accounts for roughly two-thirds of US GDP. The recent passage of Trump's tax bill could boost consumer spending in the US, help incentivize companies to bring back profits held overseas, and aid job creation in the US.
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Allegheny Technologies (ATI) concluded the recent trading session at $89.31, signifying a +1.43% move from its prior day's close.
Allegheny Technologies (ATI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
DALLAS , July 2, 2025 /PRNewswire/ -- ATI (NYSE: ATI) has scheduled the live webcast for its second quarter 2025 earnings conference call on Thursday, July 31, 2025, at 7:30 a.m. CT (8:30 a.m.
In the closing of the recent trading day, Allegheny Technologies (ATI) stood at $83.89, denoting a -2.84% move from the preceding trading day.
Here is how Allegheny Technologies (ATI) and Eldorado Gold Corporation (EGO) have performed compared to their sector so far this year.
- Potential Best-In-Class Bispecific Antibody ATI-052 Targets Both Thymic Stromal Lymphopoietin (TSLP) and Interleukin-4 Receptor (IL-4R) - WAYNE, Pa., June 23, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it has initiated a placebo-controlled Phase 1a/1b program for ATI-052, the Company's potential best-in-class investigational bispecific anti-TSLP/IL-4R antibody.
Allegheny Technologies (ATI) reached $82.18 at the closing of the latest trading day, reflecting a -2.98% change compared to its last close.